Strides Pharma Science Ltd (STAR) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported a strong quarter, emphasizing a strategic focus on profitability, geographical diversification, and balance sheet strengthening, which has yielded positive results across key financial metrics.
- A significant highlight was the performance of the ex-US markets (Other Regulated Markets and Growth Markets), which grew 20% YoY and now contribute 47% of total revenues, structurally reducing the dependency on the US market.
- Gross margins showed substantial improvement, crossing 60% and settling at 59.8% for the quarter, driven by a better product mix and the scaling down of lower-margin institutional business.
- The company achieved its highest-ever quarterly EBITDA and crossed the INR 200 crore mark in reported PAT for the first time, reflecting strong operational leverage and profitability conversion.
- Balance sheet health continued to improve, with the net debt to EBITDA ratio reduced to 1.59x and Return on Capital Employed (ROCE) increasing to 15.8%, demonstrating disciplined capital management.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.